{
    "clinical_study": {
        "@rank": "129595", 
        "arm_group": {
            "arm_group_label": "exenatide", 
            "arm_group_type": "Experimental", 
            "description": "exenatide, 5ug, bid, 3months"
        }, 
        "brief_summary": {
            "textblock": "GLP-1 receptor agonists promote fat redistribution in obese women with type 2 diabetes,\n      reduce liver fat content, improve the inflammation state"
        }, 
        "brief_title": "Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "detailed_description": {
            "textblock": "As a treatment for type 2 diabetesGlucagon like peptide -1 (Glucan-like peptide-1, GLP-1)\n      receptor agonists plays the role of promoting insulin secretion, inhibiting glucagon\n      secretion\uff0cand also has the central and peripheral effects,it can inhibit appetite,reduce\n      weight.GLP-1 receptor agonists promote fat redistribution in obese women with type 2\n      diabetes, reduce liver fat content, improve the inflammation state"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of overweight and type 2 diabetes mellitus\n\n        Exclusion Criteria:\n\n          -  Poor body condition (severe liver and kidney dysfunction)\n\n          -  Unknown causes of pancreatitis, chronic pancreatitis, pancreatic resection, stomach\n             operation, malignant tumor, previous use of systemic corticosteroids (local or\n             inhalation of exceptions) heart function or niacin, incomplete\n\n          -  serious endocrine disease\n\n          -  genetic disease"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02118376", 
            "org_study_id": "GLP-1"
        }, 
        "intervention": {
            "arm_group_label": "exenatide", 
            "description": "5ug bid,Subcutaneous injection", 
            "intervention_name": "Exenatide", 
            "intervention_type": "Drug", 
            "other_name": "Byetta"
        }, 
        "intervention_browse": {
            "mesh_term": "Exenatide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "obesity; fat distribution; inflammation", 
        "lastchanged_date": "April 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200072"
                }, 
                "name": "Shanghai Tenth People' Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status in Female Patients With Type 2 Diabetes and Obesity", 
        "other_outcome": {
            "description": "liver function", 
            "measure": "lab testing", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "overall_contact": {
            "last_name": "Yu Jie", 
            "phone": "13916674766"
        }, 
        "overall_official": {
            "affiliation": "Shang Tenth People's Hospital", 
            "last_name": "Qu Shen", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "fat distribution", 
            "measure": "Dual energy X-ray absorptiometry", 
            "safety_issue": "No", 
            "time_frame": "3 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02118376"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai 10th People's Hospital", 
            "investigator_full_name": "Zhang Manna", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "inflammation", 
            "measure": "lab testing", 
            "safety_issue": "No", 
            "time_frame": "3 month"
        }, 
        "source": "Shanghai 10th People's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai 10th People's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}